A potential breakthrough in cancer treatment
TB-403 is a humanized monoclonal
antibody against PlGF (placental
growth factor), a naturally occurring
protein that belongs to the family
of vascular endothelial growth
factors (VEGF), which promote
the formation of blood vessels.
TB-403 is intended to be used
for the treatment of cancer by
blocking the growth of both solid
tumors and metastases; and
eye diseases, where it will be
used to block uncontrolled blood
vessel growth in age-related
macular degeneration (AMD).
Toxicology studies with TB-403
were successfully completed and
therefore ThromboGenics and
BioInvent have advanced TB-403
into clinical Phase I.
The most recent published data*
show that antibodies against
PlGF can inhibit cancer tumor
growth and the development of
metastases in preclinical models,
without affecting healthy tissues.
These attractive properties are
due to PIGF inhibitors blocking the
formation of new blood vessels,
yet only in the cancer tissue.This
in contrast to currently available
products. Therefore, anti-PlGF
antibodies such as TB-403
potentially have an improved
efficacy/toxicity profile that would
be expected to inhibit angiogenesis
in diseased conditions, without,
importantly, affecting normal blood
vessels in healthy tissues.
|
All rights reserved © Thrombogenic 2006